This is the authors' abstract. We don't add key points for this paper.
Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kemp et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: